Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year.ReNeuron said it has submitted extra data for the UK's Gene Therapy Advisory Committee. If a successful review of the data is reached, the trial will get underway in the UK soon. ReNeuron said it also is now proceeding with late pre-clinical testing of the ReN009 therapy for peripheral arterial disease and will continue to liase with the regulatory authorities both in the UK and in other territories, including the US, ahead of the commencement of initial clinical trials next year.